Cargando…
Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer
BACKGROUND: Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) have shown a moderate response in colorectal cancer (CRC) with deficient mismatch repair (dMMR) functions and poor response in patients with proficient MMR (pMMR). p...
Autores principales: | Liu, Chaofan, Wang, Xi, Qin, Wan, Tu, Jingyao, Li, Chunya, Zhao, Weiheng, Ma, Li, Liu, Bo, Qiu, Hong, Yuan, Xianglin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091106/ https://www.ncbi.nlm.nih.gov/pubmed/36855844 http://dx.doi.org/10.1002/cac2.12412 |
Ejemplares similares
-
Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types
por: Terranova, Nadia, et al.
Publicado: (2020) -
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours
por: Shapiro, Geoffrey I., et al.
Publicado: (2021) -
The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines
por: Schnoell, Julia, et al.
Publicado: (2023) -
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours
por: Middleton, Mark R., et al.
Publicado: (2021) -
The application and research progress of anti-angiogenesis therapy in tumor immunotherapy
por: Tu, Jingyao, et al.
Publicado: (2023)